Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 601–700 of 1,640
Ni, M., He, J., Zhou, H.-Y., Lu, X., Hu, Y., Mao, L., Wang, F., Chen, J., & Hu, Z. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.004 · Cited by 26
Kohtala, S., Theilmann, W., Rosenholm, M., Müller, H. K., Kiuru, P. S., Wegener, G., Yli‐Kauhaluoma, J. T., & Rantamäki, T. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107684 · Cited by 29
Hare, B. D., Pothula, S., Dileone, R., & Duman, R. S. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107947 · Cited by 28
Self-citationLiu, W., Li, W., Cai, X. M., Yang, Z., Li, H., Su, X., Song, M., Zhou, D., Li, X., Zhang, C., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0659-2 · Cited by 29
Alario, A. A., & Niciu, M. J. (2021) · Chronic Stress · doi:10.1177/24705470211014210 · Cited by 26
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“By contrast, compounds with fast-acting antidepressant effects promote structural plasticity to reverse the synaptic deficits caused by chronic stress (Duman and Aghajanian, 2012).”
Geng, L., Qian, F., Qian, J.-F., & Zhang, Z. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.01.006 · Cited by 25
Shimizu, T., Ishida, A., Hagiwara, M., Ueda, Y., Hattori, A., Tajiri, N., & Hida, H. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.07.002 · Cited by 29
“Depression is associated with decreased neuronal synapses in brain regions that regulate mood and cognition, and antidepressants can reverse these neuronal deficits (Duman and Aghajanian, 2012).”
BackgroundSex Differences in the Sustained Effects of Ketamine on Resilience to Chronic Stress
Okine, T., Shepard, R. M., Lemanski, E. A., & Coutellier, L. D. (2020) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2020.581360 · Cited by 26
Zhao, Y., Wang, L., Wu, Y., Lu, Z., & Zhang, S. (2020) · Bioengineered · doi:10.1080/21655979.2020.1831349 · Cited by 27
“However, more than one-third of patients were found resistant to this drug, which limited the use of the drugs [6].”
BackgroundNi, X., Liao, Y., Li, L., Zhang, X., & Wu, Z. (2018) · Journal of Integrative Neuroscience · doi:10.3233/jin-170052 · Cited by 26
Squitti, R., Reale, G., Tondolo, V., Crescenti, D., Bellini, S., Moci, M., Caliandro, P., Padua, L., & Rongioletti, M. C. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076867 · Cited by 28
“Zn deficiency was shown to enhance the expression of NMDA receptor subunits in the hippocampus and prefrontal cortex and to decrease brain-derived neurotrophic factor (BDNF) levels essential for normal neurotransmission and neuron survival [179,180].”
BackgroundOn the significance of elektroconvulsive therapy in the treatment of severe mental diseases
Grözinger, M., Smith, E. S., & Conca, A. (2015) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0749-z · Cited by 32
Burgdorf, J. S., Colechio, E. M., Ghoreishi-Haack, N. S., Gross, A. L., Rex, C. S., Zhang, X.-L., Stanton, P. K., Kroes, R. A., & Moskal, J. R. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx007 · Cited by 30
“…used to test for rapid-acting therapeutics for PTSD. CUS induces a long-lasting and robust PTSD-like phenotype that models clinical features of PTSD and has been well characterized at the behavioral, physiological, cellular, and molecular levels (Duman and Aghajanian, 2012; Burgdorf et al., 2015b).”
BackgroundStudy on Antidepressant Activity of Pseudo-Ginsenoside HQ on Depression-Like Behavior in Mice
Chen, L., Qi, Z., Shao, Z., Li, S., Qi, Y., Gao, K., Liu, S.-X., Li, Z., Sun, Y., & Li, P. (2019) · Molecules · doi:10.3390/molecules24050870 · Cited by 27
“Major depressive disorder (MDD) is a common psychiatric disorder, which is widely distributed in the population [1,2].”
BackgroundLi, Y., Dang, X., Chen, R., Teng, Z., Wang, J., Li, S., Yue, Y., Mitchell, B. L., Zeng, Y., Yao, Y.-G., et al. (2025) · Nature Human Behaviour · doi:10.1038/s41562-024-02073-6 · Cited by 30
“Notably, some previous studies have also suggested that the synapse may have an important role in depression 8,44–48 .”
Peng, Y., Zhang, C., Su, Y., Wang, Z., & Jiang, Y. (2018) · Electrophoresis · doi:10.1002/elps.201800381 · Cited by 25
Kochanowska-Karamyan, A. J., ARAÚJO, H. C., Zhang, X., El‐Alfy, A. T., de Carvalho, P. B., Avery, M. A., Holmbo, S. D., Magolan, J., & Hamann, M. T. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01107 · Cited by 27
Chen, L., Yao, Z., Qu, S., Zhang, J., Zhang, J., Zhang, Z., Huang, Y., & Zheng, Z. (2020) · Journal of International Medical Research · doi:10.1177/0300060520918419 · Cited by 33
“One study revealed reduced hippocampal volumes in depressed patients, which were associated with neuronal atrophy, synaptic dysfunction, and synaptic loss.(10) Serotonin is an important neuroregulatory transmitter that strongly influences synaptic plasticity; 5-hydroxytryptamine (HT) can reverse these changes by inter…”
BackgroundDNA methylation in stress and depression: from biomarker to therapeutics
Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.18 · Cited by 30
Adolescent social isolation induced alterations in nucleus accumbens glutamate signalling
Deutschmann, A. U., Kirkland, J. M., & Briand, L. A. (2021) · Addiction Biology · doi:10.1111/adb.13077 · Cited by 26
Zhu, X., Li, T., Hu, E., Duan, L., Zhang, C., Wang, Y., Tang, T., Yang, Z., & Fan, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.791097 · Cited by 28
“Despite large efforts are put into developing therapies for depression, western medications are still invalid in myriad cases and regularly cause insufferable side effects (Duman and Aghajanian, 2012).”
BackgroundZhu, X., Zhang, F., You, Y., Wang, H., Yuan, S., Wu, B., Zhu, R., Liu, D., Yan, F., & Wang, Z. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01180-6 · Cited by 26
“2016; Duman and Aghajanian 2012).”
BackgroundPathophysiology of Depression: Stingless Bee Honey Promising as an Antidepressant
Zakaria, F. H., Ismail, S., Mustafa, M. Z., & Shafin, N. (2022) · Molecules · doi:10.3390/molecules27165091 · Cited by 33
“Similarly, the condition is observed in the prefrontal cortex [118,123,124] causing neuronal loss and synaptic dysfunction in cortical limbic regions that ultimately disrupt mood and emotions [73].”
BackgroundInfluentialComparison of inflammatory and behavioral responses to chronic stress in female and male mice
Medina-Rodriguez, E. M., Rice, K. C., Jope, R. S., & Beurel, E. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.08.017 · Cited by 25
The Role of Ferroptosis in Nervous System Disorders
Du, L., Wu, Y., Fan, Z., Li, Y., Guo, X., Fang, Z., & Zhang, X. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2201019 · Cited by 29
“The destruction and atrophy of neurons during depression may be the cause of this reduced volume [68,69].”
Xu, H., 王宇行, Wang, Y. M., Cao, Y., Li, P., Hu, Y., & Xia, G. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04694-z · Cited by 25
Vieira, W. F., Gersten, M. B., Caldieraro, M. A., & Cassano, P. (2023) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000363 · Cited by 28
“MDD has been associatedwith decreased volumewithin cortical and limbic brain regions (such as the prefrontal cortex [PFC] and hippocampus), neuronal atrophy, and synaptic loss.(46) Functional neuroimaging studies of the brains of depressed subjects have shown a reduction in connectivity in the hippocampus and PFC, thu…”
BackgroundLi, J., Zhang, M., Pei, Y., Yang, Q., Zheng, L., Wang, G., Sun, Y., Yang, W., & Liu, L. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116723 · Cited by 25
Antidepressant effect of licorice total flavonoids and liquiritin: A review
Wang, R., Chen, Y., Wang, Z., Cao, B., Du, J., Deng, T., Yang, M., & Han, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22251 · Cited by 35
Mikoteit, T., Hemmeter, U., Eckert, A., Brand, S., Bischof, R., Delini-Stula, A., Holsboer-Trachsler, E., & Beck, J. (2015) · Neuropsychobiology · doi:10.1159/000437439 · Cited by 25
Latchney, S. E., Masiulis, I., Zaccaria, K. J., Lagace, D. C., Powell, C. M., McCasland, J. S., & Eisch, A. J. (2014) · Developmental Neuroscience · doi:10.1159/000357840 · Cited by 28
A fragile balance: dendritic spines, learning, and memory
McCann, R. F., & Ross, D. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.020 · Cited by 27
“For instance, there are thought to be too many spines in some forms of autism spectrum disorder and too few spines in depression and Alzheimer's disease (Figure 1B) (8).”
BackgroundPeng, Z., Deng, B., Jia, J., Hou, W., Hu, S., Deng, J., Lin, W., Hou, L., & Sang, H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.014 · Cited by 27
“Coincidentally, all the above mentioned functions of LXRs activation including promoting neurogenesis and synaptic plasticity, preventing neurodegeneration, inhibiting inflammation, as well as regulating cholesterol and glucose metabolism are in line with all proposed mechanisms of action of current antidepressants (D…”
InfluentialTriclosan Impairs Hippocampal Synaptic Plasticity and Spatial Memory in Male Rats
Arias‐Cavieres, A., More, J., Vicente, J. M., Adasme, T., Hidalgo, J., Valdés, J. L., Humeres, A., Valdés-Undurraga, I., Sánchez, G., Hidalgo, C., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00429 · Cited by 31
Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery
Musazzi, L. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1822814 · Cited by 26
“Not only the treatment with rapid-acting ketamine, but also the chronic administration of traditional antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), were reported to restore synaptic plasticity, increase spine density and rescue the atrophy of dendrites caused by chronic stress exposure, wit…”
BackgroundInfluentialHolmes, P. V. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00090 · Cited by 30
Lyman, K. A., Han, Y., & Chetkovich, D. M. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1287899 · Cited by 25
Liu, W., Li, Q., Ye, B., Cao, H., Shen, F., Xu, Z., Du, W., Guo, F., Liu, J., Li, T., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00837 · Cited by 24
Boulle, F., Velthuis, H., Koedam, K., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., Gabriel, C., Mocaer, E., Franc, B., Rognan, D., et al. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.11.003 · Cited by 24
“A key mediator of the stress-induced synaptic dysfunction and neuronal atrophy often observed in the prefrontal cortex and hippocampus of mood disorder patients is the brain-derived neurotrophic factor (BDNF) (Berton and Nestler, 2006; Duman and Aghajanian, 2012).”
BackgroundGrieco, S. F., Qiao, X., Johnston, K. G., Chen, L., Nelson, R. R., Lai, C., Holmes, T. C., & Xu, X. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01255-4 · Cited by 24
Xue, K., Liu, F., Liang, S., Guo, L., Shan, Y., Xu, H., Jiao, X., Jiang, Y., Zhang, Y., & Lu, J. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.11.021 · Cited by 26
Wang, M., Zhou, W., Zhou, X. P., Zhuang, F., Chen, Q., Li, M., Ma, T., & Gu, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.039 · Cited by 27
Uchihara, Y., Tanaka, K., Asano, T., Tamura, F., & Mizushima, T. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.12.085 · Cited by 25
Qi, K., Li, R., Cai, L., Wu, S., & Li, C. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.022 · Cited by 25
Zhang, K., Liu, R., Zhang, J., Wei, X., Gao, Y., Ma, W., Li, Y., Cai, W., & Shen, W. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/2146001 · Cited by 27
Joshi, R., & Salton, S. R. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.932497 · Cited by 27
“…cells and neurons, and additionally modulates synaptic transmission in the adult hippocampus and subventricular zone (Fabel et al., 2003; McCloskey et al., 2005), neuroprotection (Feng et al., 2011), and hippocampal neurogenesis (Fournier and Duman, 2012), consistent with a potential role in MDD.”
BackgroundFonseca, C., Ettcheto, M., Bicker, J., Fernandes, M. J., Falcão, A. C., Camins, A., & Fortuna, A. C. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101998 · Cited by 32
Ghanizadeh, A. J., Singh, A., Berk, M., & Nami, M. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1019866 · Cited by 26
“Furthermore, inflammatory reactions and homocysteine-regulated pathways are considered as potential factors hampering synaptic connections in mood-related circuits [46].”
BackgroundWang, Q., Yu, C.-Y., Shi, S., Su, X., Zhang, J., Ding, Y., Sun, Y., Liu, M., Li, C., Zhao, X., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.11.069 · Cited by 27
Grape‐derived polyphenols produce antidepressant effects via VGF‐ and BDNF‐dependent mechanisms
Jiang, C. S., Sakakibara, E., Lin, W., Wang, J., Pasinetti, G. M., & Salton, S. R. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14098 · Cited by 25
Moolamalla, S. T. R., & Vinod, P. K. U. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.103994 · Cited by 25
Ren, L. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110910 · Cited by 23
“…classsical antidepressants, i.e., serotonin selective reuptake inhibitors (SSRIs), fails to provide relief to almost one in three patients with MDD, and clinical improvements in those that respond only manifest following prolonged administration over weeks or months (Duman and Aghajanian, 2012).”
BackgroundInfluentialWang, C., Li, H., Chen, C., Yao, X., Yang, C., Yu, Z., Ren, J., Ming, Y., Huang, Y., Rong, Y., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119394 · Cited by 28
“Prefrontal atrophy is a frequently reported structural neuroimaging manifestation in individuals with depression and dementia [14,48].”
BackgroundZhu, M., Chen, Y., Zheng, J., Zhao, P., Xia, M., Tang, Y., & Wang, F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03265-y · Cited by 29
“Furthermore, the study primarily reports associations rather than causal relationships, high lighting the need for further research on the interplay between genes and the brain in the context of the disease phenotype.”
Astrocyte-derived CCL5-mediated CCR5 + neutrophil infiltration drives depression pathogenesis
Yao, H. P., Jiang, S., Jiao, Y., Zhou, Z.-Y., Zhu, Z., Wang, C., Zhang, K., Ma, T. F., Hu, G., Du, R., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt6632 · Cited by 31
Kim, J., Yang, M., Kim, J., Song, L., Lee, S., Son, Y., Kang, S., Bae, C., Kim, J., Kim, S., et al. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.08.001 · Cited by 24
“Rett syndrome (Allen et al., 2011; Angelucci et al., 2005; Autry and Monteggia, 2012; Duman and Aghajanian, 2012; Liu et al., 2005; Martinowich et al., 2007; Neves-Pereira et al., 2002; Sklar et al., 2002).”
Hou, Z., Gong, L., Zhi, M., Yin, Y., Zhang, Y., Xie, C., & Yuan, Y. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9773-0 · Cited by 22
Abdoulaye, I. A., Wu, S.-S., Chibaatar, E., Yu, D., Le, K., Cao, X., & Guo, Y. (2021) · Neural Plasticity · doi:10.1155/2021/6635084 · Cited by 26
“It is well documented that chronic stress generates abnormal morphological changes in key brain regions at the ultrastructural level [66, 67].”
BackgroundKawatake-Kuno, A., Murai, T., & Uchida, S. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.749180 · Cited by 28
Han, S., Zheng, R., Li, S., Zhou, B., Jiang, Y. B., Wang, C., Wei, Y., Pang, J., Li, H., Zhang, Y., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.826609 · Cited by 25
Zhang, Q., Liu, Z., Wang, Q., & Li, X. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01645-7 · Cited by 27
“Given that the association is well demonstrated between neuronal deficits and depression [8, 9], a hypothesis has emerged that the link between depression and low cholesterol may have a neurobiological mechanism [3].”
BackgroundWeigand, A., Gärtner, M., Scheidegger, M., Wyss, P. O., Henning, A., Seifritz, E., Stippl, A., Herrera-Meléndez, A. L., Bajbouj, M., Aust, S., et al. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac049 · Cited by 22
“Depressive states are accompanied by glutamatergic system alterations such as decreased expression of NMDA and AMPA receptor subunits as well as decreased number of neurons (Rajkowska et al., 1999; Pittenger and Duman, 2008; Feyissa et al., 2009; Duman and Aghajanian, 2012; Yuen et al., 2012).”
BackgroundYi, B., Matzel, S., Feuerecker, M., Hoerl, M., Ladinig, C., Abeln, V., Choukèr, A., & Schneider, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.12.011 · Cited by 31
Hyperforin: To Be or Not to Be an Activator of TRPC(6)
Friedland, K., & Harteneck, C. (2015) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/112_2015_25 · Cited by 28
Savoy, C. D., Lieshout, R. J. V., & Steiner, M. S. (2016) · Acta Physiologica · doi:10.1111/apha.12726 · Cited by 25
“There is robust epidemiological, clinical and experimental evidence linking major depressive disorder (MDD) and cardiovascular disease (CVD) (Elderon & Whooley 2013) (Wright et al. 2014).”
BackgroundKetamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
Abdallah, C. G., & Krystal, J. H. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112628 · Cited by 23
Özkay, Ü. D., Söztutar, E., Can, Ö. D., Üçel, U. İ., Öztürk, Y., & Ulupınar, E. (2015) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000153 · Cited by 24
“Over the last few decades, it has been widely accepted that structural and cellular changes in several regions of the brain underlie the neurobiology of depression (Duman and Aghajanian, 2012).”
BackgroundKetamine may block NMDA receptors in astrocytes causing a rapid antidepressant effect
Mitterauer, B. (2012) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2012.00008 · Cited by 25
“There is experimental evidence that ketamine induces synaptogenesis leading to the synaptogenic hypothesis of depression and treatment response (Duman and Aghajanian, 2012).”
BackgroundLi, Y., Wang, H., Wang, X., Liu, Z., Wan, Q., & Wang, G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.03.008 · Cited by 24
Averill, L. A., & Abdallah, C. G. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2035358 · Cited by 23
“of chronic stress pathology (CSP) aimed to optimize, adapt, enhance, and/or modulate neural circuitry [4,12,13,32].”
BackgroundVakhitova, Y. V., Kalinina, T. S., Zainullina, L. F., Lusta, A. Y., Volkova, A. V., Kudryashov, N. V., Gudasheva, T. A., Shimshirt, A. A., Kadnikov, I. A., Voronin, M. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413381 · Cited by 21
“Numerous basic research findings confirm that typical antidepressants increase the BDNF mRNA and protein expression as well as the TrkB activation in the hippocampus and the cortex [3,7,15], thus promoting the structural plastic changes associated with the antidepressant action mechanisms [8,16,17].”
BackgroundGuo, W., Tang, Z., Cai, Z., Zhao, W., Yang, J., Wang, X., Ji, J., Huang, X., & Sun, X. (2021) · The FASEB Journal · doi:10.1096/fj.202100124rr · Cited by 23
Dysregulation of complement system in neuropsychiatric disorders: A mini review
Sierra, D. P., Tripathi, A., & Pillai, A. (2022) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2022.100056 · Cited by 25
Kasai, H. (2023) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.99.018 · Cited by 25
New design strategies for antidepressant drugs
Immadisetty, K., Geffert, L. M., Surratt, C. K., & Madura, J. D. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.830102 · Cited by 25
“Ketamine and other NMDA glutamate receptor antagonists elicit an antidepressant response within hours, as opposed to the weeks required of monoamine-based drugs [69].”
BackgroundEstradiol reverses excitatory synapse loss in a cellular model of neuropsychiatric disorders
Erli, F., Palmos, A., Raval, P., Mukherjee, J. T., Sellers, K. J., Gatford, N. J. F., Moss, S. J., Brandon, N. J., Penzes, P., & Srivastava, D. P. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0682-4 · Cited by 25
“Molecular psychiatry 2015; 20(6): 695-702.”
BackgroundEser, H. Y., Appadurai, V., Eren, C. Y., Yazıcı, D., Chen, C., Öngür, D., Pizzagalli, D. A., Werge, T. M., & Hall, M. (2020) · Acta Neuropsychiatrica · doi:10.1017/neu.2020.14 · Cited by 26
“Decreased hippocampal neurogenesis, neuronal atrophy and synaptic loss in the hippocampus represent key neurobiological findings of stress-related disorders and anhedonia (Duman & Aghajanian, 2012).”
BackgroundPhillips, J. L., Jaworska, N., Kamler, E., Bhat, V., Blier, J., Foster, J. A., Hassel, S., Ho, K., McMurray, L., Milev, R., et al. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02672-3 · Cited by 22
“The discovery of the rapid antidepressant effects of subanaesthetic doses of intravenous (IV) ketamine [5] has been described as one of the most important breakthroughs in the field of depression in the past 50 years [6].”
BackgroundMizohata, Y., Toda, H., Koga, M., Saito, T., Fujita, M., Kobayashi, T., Hatakeyama, S., & Morimoto, Y. (2021) · Human Cell · doi:10.1007/s13577-021-00553-9 · Cited by 25
“A major cause of depression is thought to be a disruption of homeostasis in neurological function in the central nervous system [9].”
BackgroundJiang, L., Peng, Y., He, R., Yang, Q., Yi, C., Li, Y., Zhu, B., Si, Y., Zhang, T., Biswal, B. B., et al. (2023) · Research · doi:10.34133/research.0171 · Cited by 25
“As for the GO biological processes, the “synaptic signaling” pathway influencing synaptic stability and maturation [48] was identified with the highest Metascape value.”
BackgroundInfluentialEsketamine versus placebo on time to remission in major depressive disorder with acute suicidality
Fu, D., Zhang, Q., Shi, L., Borentain, S., Guo, S., Mathews, M., Anjo, J., Nash, A. I., O’Hara, M., & Canuso, C. M. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05017-y · Cited by 24
“ESK, the S-enantiomer of ketamine and an N-methyl-D-aspartate receptor antagonist, acts through a primary mechanism that differs from that of traditional monoaminergic anti-depressants [13, 14].”
BackgroundMicroarray Analysis of the Major Depressive Disorder mRNA Profile Data
Gao, L., Gao, Y., Xu, E., & Xie, J. M. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.3.388 · Cited by 24
Gupta, S., Redmond, T. M., Meng, F., Tidball, A. M., Akil, H., Watson, S. J., Parent, J. M., & Uhler, M. D. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14255 · Cited by 27
Wu, T., Li, X., Li, T., Cai, M., Yu, Z., Zhang, J., Zhang, Z., Zhang, W., Xiang, J. Y., & Cai, D. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/5916451 · Cited by 31
“, cortex and hippocampus) and decreased neuronal synapses in these areas, are implicated in depression [2].”
BackgroundXie, H., Huang, H., Tang, M., Wu, Y., Huang, R., Liu, Z., Zhou, M., Liao, W., & Zhou, J. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2664-y · Cited by 25
Zhu, J., Peng, Q., Xu, Y., Xu, H., Wan, Y., Li, Z., Qiu, Y., Xia, W., Guo, Z., Li, H., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902546rr · Cited by 24
Wu, F., Sun, H., Gong, W.-G., Li, X., Pan, Z., Shan, H., & Zhang, Z. (2020) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13450 · Cited by 21
Expansion of a frontostriatal salience network in individuals with depressionPreprint
Lynch, C. J., Elbau, I., Ng, T. H. B., Ayaz, A., Zhu, S., Manfredi, N., Johnson, M., Wolk, D., Power, J. D., Gordon, E. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.551651 · Cited by 22
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice
Shen, M., Lv, D., Liu, X., & Wang, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02290-5 · Cited by 22
“Ketamine is an N-methyl-D-aspartate receptor (NMDAR) antagonist that can promote the synthesis and transmission of glutamate, activate brain-derived neurotrophic factor (BDNF)/ tropomyosin-related kinase receptor B (TrkB) signal transduction, and promote synaptic formation, thus achieving a rapid and enduring antidepr…”
BackgroundWang, Y., Jiang, H., Ni, J., & Guo, L. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01632-3 · Cited by 22
“…evaluate the action of activated sigma-1 receptors, the astrocyte was treated with (+)SKF-10047, a highly selective agonist of sigma-1 receptor at concentrations ranging from 0.1 to 10 μM for 24 h. Activated astrocyte usually involved progressive changes in proliferation (Gadea et al. 2008).”
MethodInfluentialNedd4l downregulation of NRG1 in the mPFC induces depression-like behaviour in CSDS mice
Xu, J., Guo, C.-P., Liu, Y., Wu, G.-K., Ke, D., Wang, Q., Mao, J., Wang, J.-Z., Liu, R., & Wang, X.-C. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00935-x · Cited by 24
Vitamin D3 suppresses astrocyte activation and ameliorates coal dust-induced mood disorders in mice
Zou, Y., Mu, M., Zhang, S., Li, C., Tian, K., Li, Z., Li, B., Wang, W., Cao, H., Sun, Q., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.026 · Cited by 24
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 24
“Additionally, ketamine regulates neuroplasticity by activating the mTOR signaling pathway and enhancing BDNF activity (Autry et al., 2011; Duman & Aghajanian, 2012; Dwyer & Duman, 2013; Zhou et al., 2014).”
BackgroundLi, Q., Gao, Y., Li, H., Liu, H., Wang, D., Pan, W. X., Liu, S., & Xu, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.07.037 · Cited by 22
Choi, J., Kim, J., Park, M., & Lee, H. (2022) · Nutrients · doi:10.3390/nu15010145 · Cited by 26
Wang, C., Gong, B., Liu, Y., Chen, D., Wu, Y., & Wei, J. (2023) · Biomedical Reports · doi:10.3892/br.2023.1598 · Cited by 25
Dias, L., Pochmann, D., Lemos, C., Silva, H. B. L., Real, J. I., Gonçalves, F. Q., Rial, D., Gonçalves, N., Simões, A. P., Ferreira, S. G., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00810 · Cited by 24
Kim, H., Wei, J., Call, T., Ma, X., Quintus, N. T., Summers, A. J., Carotenuto, S., Johnson, R., Nguyen, A., Cui, Y., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.03.017 · Cited by 24
Haniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 22
“…clinical and pre-clinical evidence suggesting that microgliosis in multiple brain regions, including the hippocampus, is associated with depressive-like behaviours (Butovsky et al., 2006; Duman & Aghajanian, 2012; Fan et al., 2022; Fang et al., 2023; Wang et al., 2022b; Zhang, Zhang, & You, 2018).”
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.